For patients with HER2 gene amplification of their primary breast cancer, the degree of concordance with the HER2 status of their CTCs was high, with only 1 of 45 (2%) patients demonstrating loss of HER2 amplification in the corresponding CTCs (Table 1). This evidence concerns the gene ERBB2 and breast cancer.